Wednesday was a good day for anyone who believes companies should do one thing well. CVS Health said it would split its drugstores from Aetna and Caremark, undoing the premise of its 2018 purchase of the insurer. Kraft Heinz sold control of Maxwell House to a private-equity firm. In Tokyo, a state fund that bought JSR two years ago to build a national champion is preparing to sell it to Mitsui Chemicals instead.
The common thread is that investors are paying for focus, and managers have noticed. The integrated health company, the global food portfolio and the state-sponsored platform were each sold on the promise that the whole would be worth more than the parts. The market has spent years telling them otherwise.
The case for the breakup
Breakups solve real problems. A retail pharmacy and a pharmacy-benefit manager have different capital needs, different regulators and different investors. Bundling them forces one board to allocate capital across businesses that compete for it on unequal terms, and invites the political scrutiny now aimed at vertically integrated health giants. A coffee business growing slowly inside a turnaround is a distraction for Kraft Heinz and a priority for a buyer that does nothing but carve-outs.
Separation also makes accountability clearer. When each business reports its own results, management can no longer hide a weak unit behind a strong one.
The fine print matters
But focus is not free. The glue that held these companies together does not disappear; it becomes a set of contracts. CVS says the ties between its stores and Caremark will survive through commercial agreements. Investors should read those agreements closely, because the value of the split depends on terms that one party will eventually want to renegotiate. Debt must be divided, overhead duplicated and supply arrangements rebuilt. Those dis-synergy costs are often underestimated, and the stock market’s 12% markdown of CVS on Wednesday suggests investors are not taking the promised benefits on faith.
The same day also offered the counterexample. ARRAY and Shoals agreed to combine because customers want trackers and wiring designed together. Scale still pays when it removes friction for customers. It fails when it exists mainly to make a company bigger.
That is the test boards should apply in both directions. Combine when the customer benefits; separate when the parts are being held back. The fashion of the moment favors breaking up, but the right answer depends on the business, not the cycle.
